Innovation Pharmaceuticals Inc
OTC:IPIX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sprout AI Inc
CNSX:BYFM
|
CA |
|
Bajaj Hindusthan Sugar Ltd
NSE:BAJAJHIND
|
IN |
|
UMT United Mobility Technology AG
XETRA:UMDK
|
DE |
|
H
|
Hangzhou Flariant Co Ltd
SSE:605566
|
CN |
|
China Cinda Asset Management Co Ltd
HKEX:1359
|
CN |
Innovation Pharmaceuticals Inc
Accrued Liabilities
Innovation Pharmaceuticals Inc
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Innovation Pharmaceuticals Inc
OTC:IPIX
|
Accrued Liabilities
$1.8m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-8%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accrued Liabilities
$8.2B
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accrued Liabilities
$3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
25%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accrued Liabilities
$2.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
14%
|
CAGR 10-Years
19%
|
|
Innovation Pharmaceuticals Inc
Glance View
Innovation Pharmaceuticals, Inc. is a clinical stage biotechnology company. The company is headquartered in Wakefield, Massachusetts and currently employs 4 full-time employees. The company went IPO on 2007-04-02. The firm is engaged in developing therapies with anti-inflammatory, antibiotic, antiviral, dermatology and oncology applications. The firm owns the right to numerous drug compounds, including Brilacidin, its lead drug in a class of compounds known as defensin-mimetics and Kevetrin (thioureidobutyronitrile), which is its lead anti-cancer compound. The firm's clinical trials focused on evaluating its drug candidates, including Kevetrin for the treatment of cancers and Brilacidin for treatments of Acute Bacterial Skin and Skin Structure Infection (ABSSSI), prevention of oral mucositis complicating chemoradiation treatment for cancer, and ulcerative colitis. The firm is focused on developing small molecule therapies to treat diseases in the areas of inflammatory diseases, cancer, dermatology and anti-infectives.
See Also
What is Innovation Pharmaceuticals Inc's Accrued Liabilities?
Accrued Liabilities
1.8m
USD
Based on the financial report for Sep 30, 2023, Innovation Pharmaceuticals Inc's Accrued Liabilities amounts to 1.8m USD.
What is Innovation Pharmaceuticals Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
-8%
Over the last year, the Accrued Liabilities growth was -9%. The average annual Accrued Liabilities growth rates for Innovation Pharmaceuticals Inc have been -14% over the past three years , -12% over the past five years , and -8% over the past ten years .
